Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial
Design Therapeutics (DSGN) reported second-quarter 2026 financial results and provided updates across its GeneTAC clinical pipeline, including modifications to the RESTORE-FA trial for DT-216P2 in Friedreich ataxia.
The company reported a net loss of $20.2 million for the quarter ended June 30, 2026, and said cash, cash equivalents and investment securities totaled $207.4 million at quarter-end.
- R&D expenses were $16.4 million for the quarter ended June 30, 2026.
- G&A expenses were $5.8 million for the quarter ended June 30, 2026.
- Net loss per share, basic and diluted, was $0.32 for the quarter.
- Design expects to provide an update on RESTORE-FA registrational plans in the fourth quarter of 2026.
- Data following 12 weeks of treatment in RESTORE-FA is expected in the first quarter of 2027.
- Patient dosing has started in a Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1.
- Data from DT-818 and the Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy are expected in 2027.
EARLY ACCESS
Receive DSGN Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$DSGN Hedge Fund Activity
We have seen 72 institutional investors add shares of $DSGN stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 2,649,250 shares (-49.3%) from their portfolio in Q1 2026, for an estimated $28,188,020
- RA CAPITAL MANAGEMENT, L.P. added 1,511,592 shares (+103.4%) to their portfolio in Q1 2026, for an estimated $16,083,338
- DRIEHAUS CAPITAL MANAGEMENT LLC added 565,170 shares (+47.9%) to their portfolio in Q1 2026, for an estimated $6,013,408
- LOGOS GLOBAL MANAGEMENT LP removed 550,000 shares (-22.0%) from their portfolio in Q1 2026, for an estimated $5,852,000
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 521,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $5,543,440
- BAKER BROS. ADVISORS LP added 352,879 shares (+15.8%) to their portfolio in Q1 2026, for an estimated $3,754,632
- GOLDMAN SACHS GROUP INC added 234,064 shares (+86.5%) to their portfolio in Q1 2026, for an estimated $2,490,440
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Read full article here »
View the Zacks #1 Rank List
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial
Design Therapeutics (DSGN) reported second-quarter 2026 financial results and provided updates across its GeneTAC clinical pipeline, including modifications to the RESTORE-FA trial for DT-216P2 in Friedreich ataxia.
The company reported a net loss of $20.2 million for the quarter ended June 30, 2026, and said cash, cash equivalents and investment securities totaled $207.4 million at quarter-end.
$DSGN Hedge Fund Activity
We have seen 72 institutional investors add shares of $DSGN stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Read full article here »